Loading viewer...
other
Format: PDF other
Plainview LLC short-seller report from October 2018 arguing that Nektar Therapeutics' NKTR-214 immunotherapy candidate lacks efficacy and misses clinical thresholds. The report claims the drug's mechanism does not achieve stated objectives and compares results unfavorably to competing candidates like epacadostat.
conference
28 Pages
other
19 Pages
KPMG Corporate Finance LLC
other
29 Pages
ΤΙΤΑΝ
other
38 Pages
ΤΙΤΑΝ
California Water Boards SMARTS Enhancements 2023
otherother
37 Pages
California Water Boards